Patients were randomized 1:1:1 across treatment arms. Arm A received encorafenib plus binimetinib until progressive disease [PD], followed by ipilimumab plus nivolumab until second PD. Arm B received ipilimumab plus nivolumab until PD followed by encorafenib plus binimetinib until second PD. Arm C (‘sandwich’ or ‘induction/maintenance’) received encorafenib plus binimetinib for 8 weeks followed by ipilimumab plus nivolumab until PD followed by encorafenib plus binimetinib until second PD). Patients were stratified by number of involved tumor sites and LDH elevation (IIIb/c – M1a – M1b, M1c with LDH ≤ 2ULN, and M1c with elevated LDH > 2 ULN).
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.